NASDAQ:LVTX LAVA Therapeutics (LVTX) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free LVTX Stock Alerts $3.33 -0.58 (-14.83%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$3.31▼$3.9350-Day Range$1.53▼$4.0352-Week Range$1.13▼$6.47Volume490,993 shsAverage Volume3.08 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get LAVA Therapeutics alerts: Email Address LAVA Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside80.2% Upside$6.00 Price TargetShort InterestHealthy2.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.41) to ($1.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.91 out of 5 starsMedical Sector654th out of 939 stocksPharmaceutical Preparations Industry310th out of 441 stocks 3.5 Analyst's Opinion Consensus RatingLAVA Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, LAVA Therapeutics has a forecasted upside of 80.2% from its current price of $3.33.Amount of Analyst CoverageLAVA Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.28% of the float of LAVA Therapeutics has been sold short.Short Interest Ratio / Days to CoverLAVA Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LAVA Therapeutics has recently increased by 476.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLAVA Therapeutics does not currently pay a dividend.Dividend GrowthLAVA Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LVTX. Previous Next 2.9 News and Social Media Coverage News SentimentLAVA Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for LAVA Therapeutics this week, compared to 0 articles on an average week.Search Interest38 people have searched for LVTX on MarketBeat in the last 30 days. This is an increase of 1,800% compared to the previous 30 days.MarketBeat Follows4 people have added LAVA Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LAVA Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.79% of the stock of LAVA Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for LAVA Therapeutics are expected to decrease in the coming year, from ($1.41) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LAVA Therapeutics is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LAVA Therapeutics is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLAVA Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About LAVA Therapeutics Stock (NASDAQ:LVTX)LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.Read More LVTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LVTX Stock News HeadlinesMarch 25, 2024 | americanbankingnews.comLAVA Therapeutics (NASDAQ:LVTX) Expected to Post FY2028 Earnings of ($0.65) Per ShareMarch 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for LAVA Therapeutics Amid Promising T-Cell Cancer Therapy Trials and Strong FinancialsMarch 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 22, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for LAVA Therapeutics (NASDAQ:LVTX)March 20, 2024 | finance.yahoo.comLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial ResultsMarch 20, 2024 | globenewswire.comLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial ResultsMarch 6, 2024 | finanznachrichten.deLAVA Therapeutics N.V.: LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)March 5, 2024 | msn.comLava gets $7M from Pfizer as trial for cancer drug advancesMarch 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 5, 2024 | globenewswire.comLAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)March 1, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), LAVA Therapeutics (LVTX)February 21, 2024 | benzinga.comLAVA Therapeutics Stock (NASDAQ:LVTX), Short Interest ReportFebruary 14, 2024 | investing.comLAVA Therapeutics NV (LVTX)January 25, 2024 | msn.comLava signs collaboration agreement with MSD for prostate cancer therapyJanuary 25, 2024 | seekingalpha.comPCSA, ONCO and KAVL among mid-day moversJanuary 25, 2024 | finance.yahoo.comLAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®December 13, 2023 | ca.finance.yahoo.comLAVA Therapeutics N.V. (LVTX)November 11, 2023 | morningstar.comLAVA Therapeutics NV LVTXAugust 25, 2023 | bizjournals.comLava Therapeutics is latest life sciences company to trim its workforceAugust 22, 2023 | finanznachrichten.deLAVA Therapeutics N.V.: LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsAugust 22, 2023 | finance.yahoo.comLAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsJuly 6, 2023 | msn.comLAVA Therapeutics (LVTX) Price Target Decreased by 44.62% to 7.34June 14, 2023 | finanznachrichten.deLAVA Therapeutics N.V.: LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash RunwayJune 14, 2023 | msn.comLava Therapeutics shelves hematology drug over competitive concernsJune 12, 2023 | msn.comHC Wainwright & Co. Reiterates LAVA Therapeutics (LVTX) Buy RecommendationJune 9, 2023 | markets.businessinsider.comJMP Securities Remains a Buy on LAVA Therapeutics (LVTX)June 1, 2023 | finance.yahoo.comLAVA Therapeutics to Participate in the Jefferies Healthcare ConferenceSee More Headlines Receive LVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/16/2023Today3/28/2024Next Earnings (Estimated)6/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LVTX CUSIPN/A CIK1840748 Webwww.lavatherapeutics.com Phone31-85-016-3100FaxN/AEmployees69Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+80.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,970,000.00 Net Margins-620.09% Pretax Margin-615.97% Return on Equity-68.54% Return on Assets-35.68% Debt Debt-to-Equity Ratio0.01 Current Ratio6.62 Quick Ratio6.62 Sales & Book Value Annual Sales$6.77 million Price / Sales12.47 Cash FlowN/A Price / Cash FlowN/A Book Value$3.39 per share Price / Book0.98Miscellaneous Outstanding Shares25,350,000Free FloatN/AMarket Cap$84.42 million OptionableOptionable Beta0.64 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Stephen Allen Hurly M.B.A. (Age 56)M.Sc., CEO, President & Executive Director Mr. Fred M. Powell CPA (Age 63)Chief Financial Officer Dr. Hans van der Vliet M.D. (Age 50)Ph.D., Chief Scientific Officer Ms. Amy Garabedian J.D. (Age 48)General Counsel & Corporate Secretary Mr. Wouter van HunnikVP & Head of Human ResourcesDr. Ton Adang Ph.D. (Age 63)Chief Development Officer Dr. Charles Q. Morris M.D. (Age 59)MBChB, MRCP (UK), Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsGrifolsNASDAQ:GRFSMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPPharvarisNASDAQ:PHVSProcaps GroupNASDAQ:PROCView All CompetitorsInstitutional OwnershipNovo Holdings A SSold 521,806 shares on 2/15/2024Ownership: 7.409%Citadel Advisors LLCBought 21,552 shares on 2/15/2024Ownership: 0.085%View All Institutional Transactions LVTX Stock Analysis - Frequently Asked Questions Should I buy or sell LAVA Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LAVA Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LVTX shares. View LVTX analyst ratings or view top-rated stocks. What is LAVA Therapeutics' stock price target for 2024? 2 brokers have issued 12 month target prices for LAVA Therapeutics' stock. Their LVTX share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 80.2% from the stock's current price. View analysts price targets for LVTX or view top-rated stocks among Wall Street analysts. How have LVTX shares performed in 2024? LAVA Therapeutics' stock was trading at $1.58 at the beginning of the year. Since then, LVTX stock has increased by 110.8% and is now trading at $3.33. View the best growth stocks for 2024 here. Are investors shorting LAVA Therapeutics? LAVA Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 322,100 shares, an increase of 476.2% from the February 29th total of 55,900 shares. Based on an average daily trading volume, of 1,710,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 2.3% of the company's stock are sold short. View LAVA Therapeutics' Short Interest. When is LAVA Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 13th 2024. View our LVTX earnings forecast. How were LAVA Therapeutics' earnings last quarter? LAVA Therapeutics (NASDAQ:LVTX) posted its quarterly earnings data on Thursday, November, 16th. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.15. The firm had revenue of $0.05 million for the quarter. LAVA Therapeutics had a negative net margin of 620.09% and a negative trailing twelve-month return on equity of 68.54%. When did LAVA Therapeutics IPO? LAVA Therapeutics (LVTX) raised $100 million in an IPO on Thursday, March 25th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and SVB Leerink acted as the underwriters for the IPO and Kempen & Co. was co-manager. Who are LAVA Therapeutics' major shareholders? LAVA Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Novo Holdings A S (7.41%), Citadel Advisors LLC (0.09%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of LAVA Therapeutics? Shares of LVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LVTX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryOnly a fool would buy Nvidia today… Porter & CompanyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.